American-Swiss surgical product company Alcon announced it will acquire Ivantis, makers of the minimally invasive glaucoma surgery (MIGS) device the Hydrus Microstent, for an initial US$475m.
The acquisition will allow the company to add a uniquely effective product into its glaucoma portfolio, said Alcon CEO David Endicott in a company statement citing Hydrus Microstent’s Horizon study success, where 65% of patients remained medication-free five years after implantation. “With more than 85,000 Hydrus devices implanted, now is the time to expand access globally and Alcon is the right partner as the global leader in eyecare,” said Dave Van Meter, Ivantis CEO.
The transaction is expected to be completed in early 2022.
*For more, see www.eyeonoptics.co.nz/articles/archive/glaukos-accepts-ivantis-60m-settlement